Loading stock…

Viatris Inc. (VTRS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Viatris Inc.

VTRSMarket cap $20BPrice $17.4

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Manufactures generic and brand-name drugs, treating conditions from epilepsy to HIV across 165 countries. Formed from Pfizer's Upjohn merging with Mylan, it now sells medicines cheaper than almost any rival, betting on volume over margins to stay profitable.

In Bastion Portfolios?

52W Return+76%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-4%2

Revenue Forecast

Rev CAGR (1y)+3%4

Rev CAGR (3y)+3%2

Rev CAGR (5y)+3%3

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+6%5

EPS Growth Y+3+4%5

Quality

Margins

EBIT Margin11%5

Net Income Margin-3%2

Free Cash Flow Margin13%7

Debt

Net Debt/EBITDA2.83

Efficiency

ROE-3%2

ROA-1%2

Earnings Stability44

GEAR+WEAK29

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)710

P/E Ratio (Forward 3y)610

P/BV1.48

EV Multiples

EV/EBITDA Fwd78

EV/EBIT Fwd89

Yield

Free Cash Flow Yield9.8%9

Dividend Yield2.8%7

Momentum

Short term

1 month return+6%9

3 month return+8%8

YTD return+43%9

Mid term

Price vs 52wHigh95%9

1 year return+81%10

Long term

3 year return+105%8

5 year return+58%6

Risk Shield

Price Risk

Beta1.04

Volatility32%6

Free Cash Flow

Free Cash Flow Margin13%7

Free Cash Flow Yield9.8%9

Quality

ROCE5%3

Earnings Stability44

Net Debt/EBITDA2.83

02Growth

Is it actually growing, and how fast?

VTRSViatris

Revenue FY25$14.3B

GROWTH RATING↗

WEAK16 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-4%2

Revenue, next 1Y+3%4

Revenue, next 3Y, CAGR+3%2

Revenue, next 5Y, CAGR+3%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+6%5

EPS growth, FY28E+4%5

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

After shrinking over the last 3 years, revenue is set to grow 3%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 84% of companies worldwide.

Revenue fell 4%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 3%/yr, behind 70% of companies worldwide.3/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG92 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+8%8

YTD return+43%9

MID & LONG-TERM▾SCORE

% of 52-week high95%9

1-year return+81%10

3-year return+105%8

5-year return+58%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +105% over three years and +58% over five, ahead of 60% of the market.

It's up 81% over the past year, now 5% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%), over three months (+8%) and so far this year (+43%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Viatris Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

VTRSViatris

Revenue FY25$14.3B

GROWTH RATING↗

WEAK16 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-4%2

Revenue, next 1Y+3%4

Revenue, next 3Y, CAGR+3%2

Revenue, next 5Y, CAGR+3%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+6%5

EPS growth, FY28E+4%5

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

After shrinking over the last 3 years, revenue is set to grow 3%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 84% of companies worldwide.

Revenue fell 4%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 3%/yr, behind 70% of companies worldwide.3/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG92 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+8%8

YTD return+43%9

MID & LONG-TERM▾SCORE

% of 52-week high95%9

1-year return+81%10

3-year return+105%8

5-year return+58%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +105% over three years and +58% over five, ahead of 60% of the market.

It's up 81% over the past year, now 5% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%), over three months (+8%) and so far this year (+43%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Viatris Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community